-
The results of the selection of artificial joints in the country were announced: 44 companies were selected, with an average drop of over 80%
Time of Update: 2021-10-01
On the evening of September 14, the results of the artificial joint national procurement, which has attracted much attention from the industry, were announced: 44 of the 48 companies that participated in the centralized procurement quotation this time were selected, with a winning rate of 92% .
-
What is the explanation for the “professional mismatch” status of licensed pharmacists in DTP pharmacies?
Time of Update: 2021-10-01
The lack of professional abilities of licensed pharmacists and patients' lack of understanding of the role of pharmacy services have led to the current DTP investors' belief that licensed pharmacists are only GSP requirements, and they even regard licensed pharmacists as "senior cold chain distributors.
-
The development of the medical industry has entered a period of transformation, and major companies have set off a financing boom
Time of Update: 2021-10-01
On September 16, Gaorong Technology, a minimally invasive interventional surgery robot company for tumors, announced that it has completed a Pre-A round of financing of tens of millions of yuan.
-
Li Keqiang presided over an executive meeting of the State Council to review and approve the "14th Five-Year Plan" National Medical Security Plan
Time of Update: 2021-10-01
Premier Li Keqiang of the State Council presided over an executive meeting of the State Council on September 15 to deliberate and approve the "14th Five-Year" National Medical Security Plan, deploy and improve the medical insurance system to better meet the needs of the people for medical drugs; pass the "Groundwater Management Regulations (Draft)" to strengthen Conservation and protection of groundwater resources .
-
Two pharmaceutical companies join forces to promote the commercialization of innovative domestic diabetes drugs
Time of Update: 2021-10-01
The two parties will carry out in-depth cooperation in logistics and warehousing, supply chain management and channel informatization, and jointly promote Hua Medicine’s first-in-class new drugs.
-
Viterilon's first new drug, SIR1-365 tablets, was approved for clinical use in China
Time of Update: 2021-10-01
According to Viterilon’s official website, in animal experiments, inhibiting RIP1 kinase through small molecule drugs or gene editing can effectively prevent or reduce the development of a series of diseases, including multiple sclerosis (EAE model), Alzheimer’s disease, amyotrophic lateral sclerosis, systemic inflammatory response syndrome .
-
Changsha draws a new blueprint for the development of the biopharmaceutical industry, achieving 250 billion revenue by 2025
Time of Update: 2021-10-01
Recently, according to the "14th Five-Year Plan" of Changsha's biomedical industry, by 2025, the total output value (revenue) of Changsha's biomedicine (including gene technology) industry will reach 250 billion yuan, and there will be about 30 listed companies .
-
A large number of commonly used proprietary Chinese medicines are expected to usher in a big price cut!
Time of Update: 2021-10-01
The industry believes that a batch of proprietary Chinese medicine companies will be eliminated in the future, especially small-scale and non-specialized small companies that may gradually fade out of the hospital market and move to the OTC and e-commerce markets; and have a Chinese medicinal planting base to obtain Large enterprises with advantages such as GAP certification, intelligent manufacturing, and professional promotion are expected to break through the centralized procurement competition and obtain opportunities for high-quality and rapid development .
-
The medical-grade wearable device market, which has been flooded by a large number of companies, still needs time to break out
Time of Update: 2021-10-01
For example, in 2015, "Made in China 2025" was officially released, which emphasized the need to improve the innovation capability and industrialization level of medical devices, and promote mobile Internet, cloud computing, big data and other technologies in smart Breakthrough in the manufacturing field, focusing on the development of mobile medical products such as wearables and remote diagnosis and treatment.
-
Dongfang Huakang Chinese Medicine Yiqi Tongqiao Pills Approved for Listing
Time of Update: 2021-10-01
is the holder of the marketing license for the drug .
This product is a new traditional Chinese medicine compound preparation developed on the basis of clinical experience.
-
11 companies were interviewed, unlicensed doctors were fined one million...It’s time for the "medical beauty fever" to cool down
Time of Update: 2021-10-01
In addition, the Zhejiang Provincial Health Commission recently reported a typical case of illegal medical aesthetics.
There were 761 illegal cases involving medical cosmetology institutions, with a fine of 8.
-
The first topical JAK inhibitor approved by the FDA for the treatment of atopic dermatitis
Time of Update: 2021-10-01
Incyte today announced that the US FDA has approved Opzelura (ruxolitinib) cream for short-term and non-continuous long-term treatment of patients with mild to moderate atopic dermatitis (AD) over 12 years old .
-
This targeted therapy has huge potential, and domestic and foreign pharmaceutical companies are competing for deployment
Time of Update: 2021-09-30
Recently, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Novo Nordisk has declared an oral preparation NNC0385-0434 targeting PCSK9, which has obtained the implied license for clinical trials and is planned to be developed for use in: Treatment for lowering low-density lipoprotein cholesterol (LDL-C) in adult patients with zygotic familial hypercholesterolemia, confirmed cardiovascular disease, or high cardiovascular risk, used alone or in combination with statins .
-
Chinese herbal medicines set off a wave of price increases, and the industry suggests multiple measures to break through
Time of Update: 2021-09-30
The prices of 60% of Chinese medicinal materials have risen to varying degrees, and some medicinal materials have even increased by more than 100% .
At present, a large number of Chinese medicine companies have been affected in the context of the continuous price increase of Chinese medicinal materials .
-
BMS submitted LAG-3+PD-1 fixed-dose compound market application and received FDA priority review
Time of Update: 2021-09-30
The results showed that the fixed-dose combination of relatlimab and nivolumab as a first-line therapy for previously untreated patients with metastatic or unresectable melanoma achieved statistically and clinically significant progression-free survival (PFS) benefits compared to Opdivo monotherapy (10.
-
The Sci-tech Innovation Board has tightened supervision, and another pharmaceutical company's IPO has been denied
Time of Update: 2021-09-30
Following the rejection of the Haihe Pharmaceutical Science and Technology Innovation Board IPO on September 17, another pharmaceutical company was rejected recently . On September 22, public inform
-
Following PD-1, CAR-T, and ADC, another drug has become a new trend!
Time of Update: 2021-09-30
With more and more companies in the field of anti-double-antibodies, the phenomenon of R&D may appear in the future, the track will also become crowded, and the homogenization competition will become more intense.
-
Lion Biotech announces that the FDA has approved the IND clinical application of its leading product LioCyx-M004 for the treatment of hepatocellular carcinoma
Time of Update: 2021-09-30
This new drug approval allows Lion Biotech to start an IND clinical trial of its leading product LioCyx-M004 for the treatment of primary HBV-related advanced hepatocellular carcinoma (HCC) .
-
The medical market has a bright future, and Internet companies are accelerating their deployment
Time of Update: 2021-09-30
Specifically, on September 9, 2021, ByteDance invested in two companies through its wholly-owned subsidiary Xiaohe Health, namely Beijing Meizhongyihe Medical Management (Group) Co.
Industry analysts believe that it is obvious from the above that Bytedance's layout in the medical and health field is deepening from offline medical to asset-heavy medical services .
-
Home-made cell therapy equipment ushered in a golden age with broad development space
Time of Update: 2021-09-30
On September 7th, a total of 23 institutions investigated Tailin Biology, focusing on the research and development history of key cell therapy equipment, the market space of cell therapy equipment, and the main technical barriers of the company's products .
